• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biosimilars legislation approved in New Jersey

Biosimilars legislation approved in New Jersey

November 11, 2015
CenterWatch Staff

Legislation sponsored by Assembly Democrats of the New Jersey General Assembly (Pamela Lampitt, Daniel Benson, Shavonda Sumter, Nancy Pinkin, and Herb Conaway Jr., M.D.) to make it easier for consumers to obtain more cost-effective, “generic” versions of biological medicines used to treat conditions such as rheumatoid arthritis, anemia, psoriasis and various forms of cancer has been signed into law.

“The FDA has created a safe pathway to make alternative biological medicines more readily available on the market,” said Lampitt (D-Camden/Burlington). “If there is a more cost-effective option to treat and cure various illnesses, then by all means we should be helping patients pursue it.”

“Substitution of these biologically similar products for their name-brand counterparts at the pharmacy level is expected to reduce cost by increasing competition,” said Conaway (D-Burlington). “Ultimately, this will allow more patients to access treatments.”

While New Jersey has allowed chemically synthesized generic drugs to be substituted for brand-name prescriptions for quite some time because the active ingredients are identical to their brand-name counterparts, biological medicines are manufactured through biotechnology using living organisms and are much more complex than traditional, chemically synthesized drugs.

Changes created under the federal “Patient Protection and Affordable Care Act,” however, made it easier for biosimilar biological products to gain licensure from the FDA. Over the past 18 months, about 23 states have considered legislation, establishing state standards for the substitution of biosimilar prescription products and as of Dec. 31, 2014, eight states had enacted statutes.

The new law (A-2477) adds New Jersey to that list, allowing for the substitution of biosimilar products by pharmacists, provided the conditions set forth in the law are met.

Under the law, a pharmacist who substitutes a biological product must record, on the prescription label and record of dispensing, the product name and manufacturer of the biological product dispensed, followed by the words “substituted for” and the name of the biological product for which the prescription was written. The same recordkeeping requirements as apply to the dispensing of drugs will apply to the dispensing of biological products.

The law provides immunity from liability for a pharmacist who makes such substitutions in compliance with the law to the same extent that immunity would be provided for dispensing the prescribed biological reference product.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing